Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MAFLD and CKD: An Updated Narrative Review
Alessandro Mantovani, Rosa Lombardi, Filippo Cattazzo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7007-7007
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 53
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
David R. Riley, Theresa Hydes, Gema Hernadez, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2538-2550
Open Access | Times Cited: 9
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 36
Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms
Canxia Shi, Sanne de Wit, Emina Učambarlić, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 729-729
Open Access | Times Cited: 20
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 7
Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy
Aleksander Owczarek, Joanna Musialik, Adrian Stefański, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPARα Pathway
Yifan Wang, Yudian Zhang, Yutong Wang
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1051-1051
Open Access
Nonalcoholic fatty liver disease and chronic kidney disease: random connections or two manifestations of metabolic syndrome?
Н. С. Карпунина, О. В. Хлынова
Experimental and Clinical Gastroenterology (2025), Iss. 8, pp. 123-130
Closed Access
Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan
Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 12, pp. 1559-1570
Closed Access | Times Cited: 3
Therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study
Haniyeh Keyghobadi, Hadis bozorgpoursavadjani, Farhad Koohpeyma, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 3
Exploring Adiposity and Chronic Kidney Disease: Clinical Implications, Management Strategies, Prognostic Considerations
Laşin Özbek, Sama Mahmoud Abdel‐Rahman, S. Ünlü, et al.
Medicina (2024) Vol. 60, Iss. 10, pp. 1668-1668
Open Access | Times Cited: 3
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Damien Chua, Zun Siong Low, Guo Xiang Cheam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14762-14762
Open Access | Times Cited: 12
Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
Michele Nardolillo, F. Rescigno, Mario Bartiromo, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 15, pp. 2081-2086
Open Access | Times Cited: 2
Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions
А.Е. Абатуров, Anna Nikulina
CHILD`S HEALTH (2024) Vol. 19, Iss. 2, pp. 107-116
Open Access | Times Cited: 2
What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives
Carlo Alfieri, Paolo Molinari, Felice Cinque, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7728-7728
Open Access | Times Cited: 2
Methyl Cinnamate (MC) Alleviates Free Fatty Acids (FFAs) Induced Lipid Accumulation Through the AMPK Pathway in HepG2 Cells
Yingda Fu, Guangbing Li, Zichen Feng, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1183-1197
Open Access | Times Cited: 1
Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
Salvador Benlloch, Francesc Moncho, José Luis Górriz
Nefrología (English Edition) (2024) Vol. 44, Iss. 2, pp. 129-138
Open Access | Times Cited: 1
Epicardial and liver fat implications in albuminuria: a retrospective study
Carolina M. Perdomo, Nerea Martín‐Calvo, Ana Ezponda, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
Mehmet Kanbay, Mazlum Çöpür, Mustafa Güldan, et al.
European Journal of Clinical Investigation (2024)
Open Access | Times Cited: 1
Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study
Josh Bilson, Theresa Hydes, Declan McDonnell, et al.
Liver International (2024)
Open Access | Times Cited: 1
Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
Andrea Dalbeni, Marta Garbin, Mirko Zoncapè, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15837-15837
Open Access | Times Cited: 4
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
Ruimin Lai, L.D. Yao, Shan Lin, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 103-112
Open Access
Economic impact of metabolic dysfunction-associated steatotic liver (MASLD) in Italy. Analysis and perspectives
Enrico Torre, Sergio Di Matteo, Chiara Martinotti, et al.
Research Square (Research Square) (2024)
Open Access
MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: A cross‐sectional population study
Manuela Abbate, Aneliya Parvanova, Ángel Arturo López‐González, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 4
Closed Access
Impact of High-Temperature Feeds on Gut Microbiota and MAFLD
Lijun Xue, Kaimin Li, Yanfei Jia, et al.
Journal of Microbiology and Biotechnology (2024) Vol. 34, Iss. 9, pp. 1789-1802
Open Access
Page 1 - Next Page

Scroll to top